Archive · 4 Aug 2025
Sanofi Consumer Healthcare Reports Q2 Performance
Imagine a company called Sanofi that makes healthcare products.
In a recent three-month period, they made a lot of money, about ₹220 crore, thanks to selling their products and exporting them to other countries.
Their profit, which is what they earned after paying all the costs, was ₹60 crore.
They also started selling some products again that they had to take back for a while, like Depura 60k and Combiflam Suspension, and launched a new product for allergies called Allegra D. The company says it's doing well because of their focused strategy and creating new products.
Sanofi Consumer Healthcare India's Q2 revenue reached ₹220 crore.
Profit After Tax (PAT) for the quarter was ₹60 crore.
Growth was driven by exports and product launches, as stated by the company.
The company relaunched recalled products like Depura 60k and Combiflam Suspension.
New product launches included Allegra D (allergy).
- Who
- Sanofi Consumer Healthcare India.
- What
- Sanofi Consumer Healthcare India reported Q2 financial results.
- When
- The second quarter ended on June 30, 2025.
- Where
- India.
- Why
- Growth was fueled by a focused portfolio, research-led innovation and exports.
- Q2 Revenue
- ₹220 crore
- PAT
- ₹60 crore
- Managing Director
- Himanshu Bakshi
- Products Launched
- Allegra D (allergy)
- Products Relaunched
- Depura 60k, Combiflam Suspension